Watch BCAX. Know when insiders buy.
One email the day a filing lands. Free.
BCAX
Bicara Therapeutics Inc.
23.71
+0.54 +2.33%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
29
FLAG · shorts 29
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.6BP/E —DIV YIELD —FCF YIELD -8.62%REV TTM —NET INCOME −$185.4MNET CASH —52W 10.44 – 30.40SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$60M | −$55.4M | — | -0.82 | −$44.2M | $60K | −$44.3M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$60.2M | −$56.2M | — | -0.93 | −$37.5M | $60K | −$37.6M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$41.1M | −$37.4M | — | -0.68 | −$23.9M | $238K | −$24.1M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$40.7M | −$36.3M | — | -0.67 | −$29.2M | $42K | −$29.3M | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$32M | −$27.4M | — | -0.50 | −$25.6M | $0 | −$25.6M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$41.8M | −$36.8M | — | -0.68 | −$28.1M | $0 | −$28.1M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$26.6M | −$21M | — | 7.22 | −$30M | $40K | −$30.1M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$20.6M | −$17.5M | — | -1.60 | −$17.2M | $8K | −$17.2M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$19.8M | −$17M | — | -19.01 | −$12.9M | $19K | −$12.9M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$15.4M | −$12.5M | — | -18.94 | −$14.6M | $4K | −$14.6M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.7M | −$12.4M | — | -19.43 | −$8M | $436K | −$8.5M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$9.5M | −$22.8M | — | -38.23 | — | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$155.6M | −$137.9M | — | -2.52 | −$106.8M | $280K | −$107.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$82.4M | −$68M | — | -4.05 | −$74.8M | $71K | −$74.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$39.9M | −$52M | — | -89.61 | −$45.6M | $586K | −$46.2M | — | — |
Every number comes from Bicara Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.